Bruker is expanding its life sciences business into human physiology-relevant disease models with a majority investment in MIMETAS, a Leiden-based developer of organ-on-a-chip platforms and advanced human tissue models. Financial terms were not disclosed. MIMETAS will continue to operate under its existing brand and management.
The strategic logic is straightforward: MIMETAS provides the human tissue models, while Bruker brings technologies for proteomics, metabolomics, NMR, spatial biology and preclinical imaging. The companies aim to connect the two into integrated workflows for disease research, compound testing and drug development.
MIMETAS’ flagship OrganoPlate platform uses microfluidic tissue cultures in a format compatible with standard high-throughput laboratory workflows. Its portfolio includes models for vascularized tissues, liver, lung and gut, as well as organoid-derived models. The company also offers OrganoReady tissue and organoid products, instrumentation and contract research services.
“Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates,” Bruker CEO Frank H. Laukien said. He described microphysiological systems (MPS), also known as New Approach Methodologies (NAMs), as having a “bright future” in drug discovery, development and preclinical testing.
From organoids to industrial workflows
The MIMETAS transaction matters because it is less about a single organoid model than about the industrialization of human-relevant biology. Organoids, 3D microtissues and organ-on-a-chip systems can reproduce aspects of human tissue architecture and function that are difficult to capture with conventional two-dimensional cell cultures. In drug development, their potential applications range from target validation and disease modeling to efficacy and toxicity testing.
They are not, however, a universal replacement for animal studies. Standardization, reproducibility, scalability and the ability of individual models to predict clinical outcomes remain important challenges. The growing interest in combining these models with automated screening, imaging and molecular profiling reflects an attempt to address some of those limitations.
That is where Bruker’s position becomes particularly relevant. Instead of simply adding another cell model to its portfolio, the company can connect human tissue systems with increasingly sophisticated molecular and spatial readouts. The resulting data could ultimately feed into computational and AI-based drug discovery workflows.
Europe is already consolidating the field
Bruker’s move also fits into a broader European consolidation of technologies around organoids, 3D cell models and advanced in-vitro testing. Merck KGaA acquired Dutch organoid specialist HUB Organoids in late 2024. The Utrecht-based company developed organoid technologies that complement Merck’s existing life sciences portfolio of cell culture products, reagents and research tools.
Sartorius made a similar move in 2025, agreeing to acquire MatTek, including Visikol, from Swedish BICO Group for $80 million. The transaction added 3D microtissue models and primary cells to Sartorius’ cell technology portfolio. MatTek’s models are designed to mimic human tissue structure and function and complement Sartorius’ cell analysis instruments, reagents and AI-supported models. Sartorius completed the acquisition on July 1, 2025.
The transaction also illustrates a wider reshaping of the sector. BICO itself had acquired MatTek in 2021 but later decided to divest the business as it refocused on lab automation and selected workflows.
In other words, the technology is moving in two directions at once: specialist companies are developing increasingly sophisticated human models, while larger life sciences companies are integrating those models into broader laboratory and drug-development ecosystems.
A European strength with global ambitions
There is a notable European footprint in this emerging market. MIMETAS and HUB Organoids are both Dutch companies, while Sartorius has built its cell technology strategy around its German base. Switzerland’s InSphero, meanwhile, has established itself as another major European player in 3D cell and microtissue models.
This gives Europe a meaningful position in a field that sits at the intersection of biotechnology, laboratory technology and drug development. The regulatory environment is also moving in the same direction, although adoption remains uneven. The broader NAM concept encompasses technologies ranging from organoids and organ-on-a-chip systems to computational models and other human-relevant approaches intended to improve or reduce the use of traditional animal testing.
The real prize is the data
For Bruker, the long-term opportunity may therefore lie less in selling organoids than in capturing better biological data from them. A human tissue model becomes considerably more valuable when it can be combined with automated experiments, high-content imaging, spatial biology, proteomics and metabolomics. That creates a potential feedback loop in which increasingly human-relevant models generate increasingly detailed datasets for drug discovery and, eventually, AI models.
This is also why the MIMETAS deal belongs in the wider conversation about the changing infrastructure of drug R&D. The industry is gradually moving away from isolated tools toward connected platforms that link biology, measurement, automation and computation.
Bruker’s investment in MIMETAS is another indication that organoids and microphysiological systems are no longer being viewed simply as promising alternatives to conventional cell culture. They are increasingly becoming part of the commercial infrastructure for the next generation of drug discovery.
Sign up for our newsletter!
